USAEUROPEViVE
ABOUTSPONSORSHIPFOUNDATION
Logo Hlth
Logo Hlth
20 Oct 2022 | 02:45 PM GMT

The Drop in DTx Investments: What are the implications

Anchored by:

Ed Kliphuis
Partner
SOFINNOVA PARTNERS

Participants:

Ed Kliphuis PartnerSofinnova Partners
Ed Kliphuis
PartnerSofinnova Partners
Aahuti Rai NED, Advisor & Venture PartnerFour Points Health | Conduit Connect
Aahuti Rai
NED, Advisor & Venture PartnerFour Points Health | Conduit Connect
Alex Merwin Head of Growth, Healthcare StartupsAmazon Web Services
Alex Merwin
Head of Growth, Healthcare StartupsAmazon Web Services
Jeff Wandzura CEOKEEP Labs
Jeff Wandzura
CEOKEEP Labs
Piotr Sokolowski Chief Medtech StrategistS3 Connected Health
Piotr Sokolowski
Chief Medtech StrategistS3 Connected Health
SE
Stephen Egan DirectorRediCare
SE
Stephen Egan
DirectorRediCare
Stephen Egan DirectorRedicare
Stephen Egan
DirectorRedicare
Zina Manji Founder/Principal, Regulatory StrategistInnopathwayz, LLC
Zina Manji
Founder/Principal, Regulatory StrategistInnopathwayz, LLC

About this Meeting

When the pandemic was hitting the world, venture capitalists invested more than ever in Digital Therapeutics (DTx) as the world was moving away from the traditional in-person care settings, and patients needed new ways to access care and treatments. But in 2022 things are changing, and we are witnessing a drop in investments.  

What are the reasons why venture capitalists (VC) are not investing in DTx as much as they did in the previous years? What are the implications of this? Join this discussion to have a closer look at:  

  • How can DTx startups navigate the new health tech funding landscape after the drop in 2022? How is this impacting smaller startups, but also more established and mature DTx companies?  
  • What are the factors that might be influencing this drop (e.g. European political/conflict situation, upcoming recession, the market is more crowded and competitive, etc.)? How will this situation evolve in the next year? 
  • With fewer investments in DTx solutions, startups need to find a way to stand out and get VC to invest. What is needed for small companies to have space in such a demanding and crowded market?   
  • In the search for investors, other than VC, another opportunity could be getting the investment from Pharma or MedTech companies. Should companies move towards Pharma and/or MedTech to secure investments? Will Pharma/MedTech be more open and start making more experimental partnerships and fund newer and less mature companies?  
  • Does this new landscape give a larger role to Pharma and MedTech companies?